Home > Back to Publisher > Report Information

United States Pharmaceutical Sector Report (2011 Edition)

Synergyst
July 1, 2011
73 Pages - SKU: SYGR6504952

Abstract Table of Contents Search inside this report Related Reports

Countries covered: United States

United States is world’s largest spender on healthcare at an estimated 16% of GDP in 2010. This spending is likely to continue to grow at a faster pace in the light of healthcare reforms of 2010 that extended insurance to around 45.7 million residents. United States is the single largest pharmaceutical market globally, accounting for more than 40% of the world's pharmaceutical sales. Over the past two years, however, the U.S. pharmaceutical industry has faced a number of macroeconomic challenges and industry specific issues such as inflation, government healthcare policy, declining levels of innovation, patent losses, among others. The pharmaceutical market in United States is estimated at US$338 billion, growing at 2.5% since 2009 and at a CAGR of 4.5% since 2004. Prescription drugs account for the largest share (88.6%) of total pharmaceutical sales followed by OTC drugs (8.2%) and Alternative Medication (3.2%).

Synergyst’s “United States Pharmaceutical Sector Report (2011 Edition)” is a comprehensive assessment of to the U.S. pharmaceutical market and the trends that are prevailing in the market. Report analyses healthcare, economic and policy environment in the country and presents the SWOT analysis of the country’s pharmaceutical sector. Dynamics of the industry are presented by evaluating the industry structure and estimation of market size, both in terms of volume and dollar value. Market sizing and forecast is provided for the overall market and all the segments from 2005 to 2015. Report also looks at trends that are impacting the pharmaceutical sales in United States and assess the competitive landscape in the industry.

I. EXECUTIVE SUMMARY
II. INDUSTRY OVERVIEW: a. Macroeconomic Trends; b. Healthcare Trends; c. International Trends; d. Policy Trends; e. SWOT Analysis of U.S. Pharmaceutical Industry
III. PHARMACEUTICAL SECTOR IN UNITED STATES: a. Market Structure; b. Market Size; c. Key Market Segments
IV. MARKET FORECAST
V. TRENDS AND FACTORS IMPACT ANALYSIS: a. Growth of Generics; b. Patent Expiration; c. Drug Pricing; d. Outsourcing and Pharmerging; e. Changing Demographics; f. Alternative Medication Trends; g. Research and Development; h. Import and Export Trends; i. Active Pharmaceutical Ingredient Manufacturing; j. Consolidation and M&A
VI. MARKET COMPETITION: a. Market Share of Major Players; b. Profiles of Major Players; c. Financials of Major Players; d. SWOT Analysis of Major Players
VII. APPENDIX AND GLOSSARY: a. Comparative Financials of Companies Discussed; b. Glossary of Terms
LIST OF FIGURES: Figure 1: World - Pharmaceutical Industry Revenues and Growth (2000-2010); Figure 2: United States - Market Structure of Pharmaceutical Industry; Figure 3: United States - Leading Pharmaceutical Wholesale Distributors (2010); Figure 4: United States - Share of Prescribed Drug Sales by Retail Channel (2010); Figure 5: United States - Market Share of Prescription Drug Sales Volume by Retail Channel (2006-2010); Figure 6: United States - Leading Pharmaceutical Drug Retailers (2010); Figure 7: United States - Sales Volume of Oral Standard Units and Injectable Standard Units (2006-2010); Figure 8: United States - Prescription Pharmaceutical Volume and Dollar Sales (2006-2010); Figure 9: United States - Pharmaceutical Industry Revenues and Growth (2005-2010); Figure 10: United States - Pharmaceutical Sales by Prescription Therapeutic Classes (2010); Figure 11: United States - Branded Pharmaceutical Sales and Growth (2005-2015); Figure 12: United States - Generic Pharmaceutical Sales and Growth (2005-2015); Figure 13: United States - Over-The-Counter (OTC) Pharmaceutical Sales and Growth (2005-2015); Figure 14: United States - Alternative Medication Sales and Growth (2005-2015); Figure 15: United States - Forecast for Pharmaceutical Sales and Growth (2009-2015); Figure 16: United States - Share of Generic Pharmaceutical as Prescription Sales (2005-2010); Figure 17: United States - Pricing Trends of Branded Drugs vis-à-vis Inflation (2005-2009); Figure 18: United States - Price Inflation of Top 10 Pharmaceutical Products (2009); Figure 19: United States - Forecast of Changes in 65+ Years Age Population (2000-2050); Figure 20: United States - Demographic Trends in Alternative Medication (2010); Figure 21: United States - R&D Spending by Pharmaceutical Industry (2005-2010); Figure 22: United States - R&D Spending by Leading Pharmaceutical Companies (2010); Figure 23: United States - Leading Import and Export Destinations for Pharmaceutical Industry (2010); Figure 24: United States - Leading Pharmaceutical Companies by Market Share (2010); Figure 25: AstraZeneca Plc - Annual Sales and Profits (2006-2010); Figure 26: Eli Lilly & Co. - Annual Sales and Profits (2006-2010); Figure 27: Johnson & Johnson - Annual Sales and Profits (2006-2010); Figure 28: Merck & Co., Inc. - Annual Sales and Profits (2006-2010); Figure 29: Mylan Inc. - Annual Sales and Profits (2006-2010); Figure 30: Novartis AG - Annual Sales and Profits (2006-2010); Figure 31: Pfizer Inc. - Annual Sales and Profits (2006-2010); Figure 32: Teva Pharmaceutical Industries Ltd. - Annual Sales and Profits (2006-2010)
LIST OF TABLES: Table 1: United States - Economic Growth Forecast (2010-2015); Table 2: United States - Macroeconomic Trends and Statistics (2006-2012); Table 3: United States - Healthcare Spending and Related Trends (2006-2012); Table 4: United States - Comparative Healthcare Spending vis-à-vis Other Countries (2006-2015); Table 5: United States - Prescription Drug Sales by Retail Channel (2006-2010); Table 6: United States - Market Share of PBM Companies by Sales Volume (2010); Table 7: United States - Segmentation of Pharmaceutical Industry (2005-2010); Table 8: United States - Top 10 Pharmaceutical Therapeutic Classes by Sales (2006-2010); Table 9: United States - Top 20 Prescription Drugs by Sales (2006-2010); Table 10: United States - Forecast for Pharmaceutical Industry Segments (2010-2015); Table 11: Patent Expiration and Revenue Loss to Companies (2011-2013); Table 12: United States - R&D Spending by Leading Pharmaceutical Companies (2006-2010); Table 13: United States - Recent M&A Trends in Pharmaceutical Industry; Table 14: United States - Leading Companies by Pharmaceutical Sales (2006-2010); Table 15: Summary of Income Statements of Companies Discussed (2008-2010); Table 16: Summary of Balance Sheet of Companies Discussed (2010); Table 17: Summary of Key Ratios of Companies Discussed (2010)

More United States Prescription Drugs Reports

2012 Healthcare Business Market Research Handbook by Richard K. Miller & Associates
The 2012 Healthcare Business Market Research Handbook presents a comprehensive analysis of the $2.8 trillion U.S. healthcare marketplace with the most recent statistics and data ...

Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report by IBISWorld
Brand Name Pharmaceutical Manufacturing in the US Prescription for growth With healthcare reform allowing more individuals to gain prescription coverage, brand-name pharmaceutical and medicine manufacturers will experience ...

Analysis of the United States Contract Manufacturing Outsourcing Market by Frost & Sullivan
Contract manufacturing outsourcing (CMO) companies provide independent manufacturing services for pharmaceutical and biotechnological markets. This study covers the U.S. commercial manufacturing and packaging of pharmaceutical ...

United States Pharmaceuticals and Healthcare Report Q2 2012 by Business Monitor International
BMI View: Economics and politics are increasingly exerting an influence on the US pharmaceuticalmarket. This is in stark contrast to the late 1990s and early ...

The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment by AM Mindpower Solutions
EXECUTIVE SUMMARY The report titled “The US Pharmaceutical Market Outlook to 2015 – Evolving Opportunities in the Biologics Segment” provides a comprehensive analysis on the Pharmaceutical ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>

United States Pharmaceutical Sector Report (2011 Edition)

Share this report

Other tasks

Research Assistance

Related Markets

Prescription Drugs Reports

Free Alert Me service